Page last updated: 2024-12-08

hamayne

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hamayne: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID443670
CHEMBL ID3916492
CHEBI ID31667
MeSH IDM0569972

Synonyms (10)

Synonym
hamayne
C12164 ,
61948-11-6
bulbispermine
CHEBI:31667
CHEMBL3916492
DTXSID90332125
hamayne (bulbispermine)
(1s,13s,15r,18r)-5,7-dioxa-12-azapentacyclo[10.5.2.01,13.02,10.04,8]nonadeca-2,4(8),9,16-tetraene-15,18-diol
(3r,4as,5s,11bs,12r)-3,4,4a,6-tetrahydro-11b,5-ethano[1,3]dioxolo[4,5-j]phenanthridine-3,12-diol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
alkaloidAny of the naturally occurring, basic nitrogen compounds (mostly heterocyclic) occurring mostly in the plant kingdom, but also found in bacteria, fungi, and animals. By extension, certain neutral compounds biogenetically related to basic alkaloids are also classed as alkaloids. Amino acids, peptides, proteins, nucleotides, nucleic acids, amino sugars and antibiotics are not normally regarded as alkaloids. Compounds in which the nitrogen is exocyclic (dopamine, mescaline, serotonin, etc.) are usually classed as amines rather than alkaloids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID1317835Antiproliferative activity against drug-resistant human U87 cells after 48 to 96 hrs by MTT assay2016European journal of medicinal chemistry, Sep-14, Volume: 1205,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells.
AID1317839Antiproliferative activity against patient-derived TMZ-resistant GBM 031810 cells over-expressing MGMT after 48 to 96 hrs by MTT assay2016European journal of medicinal chemistry, Sep-14, Volume: 1205,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells.
AID1317833Antiproliferative activity against drug-resistant human U373 cells after 48 to 96 hrs by MTT assay2016European journal of medicinal chemistry, Sep-14, Volume: 1205,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells.
AID1317836Antiproliferative activity against drug-resistant human T98G cells after 48 to 96 hrs by MTT assay2016European journal of medicinal chemistry, Sep-14, Volume: 1205,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells.
AID1317837Antiproliferative activity against drug-resistant human A549 cells after 48 to 96 hrs by MTT assay2016European journal of medicinal chemistry, Sep-14, Volume: 1205,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells.
AID1317832Antiproliferative activity against drug-sensitive human Hs683 cells after 48 to 96 hrs by MTT assay2016European journal of medicinal chemistry, Sep-14, Volume: 1205,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells.
AID1317834Antiproliferative activity against drug-resistant human U251 cells after 48 to 96 hrs by MTT assay2016European journal of medicinal chemistry, Sep-14, Volume: 1205,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells.
AID1317841Antiproliferative activity against patient-derived paclitaxel-resistant NCI-H2073 cells after 48 to 96 hrs by MTT assay2016European journal of medicinal chemistry, Sep-14, Volume: 1205,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells.
AID1317842Antiproliferative activity against human MES-SA cells after 48 to 96 hrs by MTT assay2016European journal of medicinal chemistry, Sep-14, Volume: 1205,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells.
AID1317843Antiproliferative activity against human MES-SA/Dx5 cells after 48 to 96 hrs by MTT assay2016European journal of medicinal chemistry, Sep-14, Volume: 1205,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells.
AID1317840Antiproliferative activity against patient-derived paclitaxel-sensitive NCI-H1993 cells after 48 to 96 hrs by MTT assay2016European journal of medicinal chemistry, Sep-14, Volume: 1205,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells.
AID1317838Antiproliferative activity against patient-derived TMZ-sensitive GBM 090909 cells after 48 to 96 hrs by MTT assay2016European journal of medicinal chemistry, Sep-14, Volume: 1205,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.35 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]